All News

manpower.cliff.shortage

Rheumatology Shortage Cliff in Australia & USA

Jack Cush, MD

Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States.

Read Article
RA,polyarticular,black,rheumatoid

ACPA and the Transition from Arthralgia to Rheumatoid Arthritis

MedPage Today

Patients with clinically suspect arthralgia (CSA), a common prequel to rheumatoid arthritis (RA), showed different patterns of symptoms and progression depending on whether they tested positive for anti-citrullinated protein antibodies (ACPA), researchers found.

Read Article
PsA.Xray_.Erosion.Cup_.jpg

Guselkumab gets FDA Nod for X-ray Protection

Jack Cush, MD

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's supplemental Biologics License (sBLA) to include evidence in the guselkumab (Tremfya) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA). 

Read Article
RheumNow Podcast square

Count Your Telangiectasias (5.29.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and missed quiz questions.

Read Article
drug%20interactions.jpg

Increased Polypharmacy in SLE Patients

Jack Cush, MD

A cross-sectional study of US adults with systemic lupus erythematosus (SLE) shows significantly increased prevalence of polypharmacy, related to age, disease outcomes and often, non-SLE common medications.

Read Article
T2T.RA2_.jpg

Integrating D2T into T2T Practices in RA

EurekAlert!

Researchers at Semmelweis University analyzed how depression, smoking, obesity, sleep disorders, and other health problems are linked to difficult-to-treat rheumatoid arthritis (D2T-RA) and how this can inform treat-to-target (T2T) and individualized therapy.

Read Article
LRA.logo

LRA Awards for Immune Resetting Therapies in Lupus

Lupus Research Alliance

Lupus Research Alliance (LRA), the world’s largest private funder of lupus research, in collaboration with Genentech, a member of the Roche Group, announced the inaugural recipients of t

Read Article
Sjogren's on chalkboard

RepurpSS-II: Hydroxychloroquine plus Leflunomide in Sjögren's

Jack Cush, MD

A small, pilot, phase 2b trial has shown that the combination of leflunomide and hydroxychloroquine (LEF+HCQ) was effective and safe in treating patients with active Sjögren's disease.

Read Article
lupus.nephritis.immunofluorescence.jpg

Trends and Innovations in Lupus Nephritis Clinical Trials

Jack Cush, MD

Xu et al. from Shanghai University have written an analysis of global lupus nephritis (LN) clinical trials and call for innovation.

Read Article
🎯 Does Tofacitinib work in axial #PsA? #POS0049: 1st RCT (PASTOR, n=26): improved MRI & clinical outcomes vs placebo @ wk12 #EULAR2026 @rheumnow

Nelly ZIADE 🍀 Nellziade ( View Tweet)

Nail #PsA, hard to treat and often overlooked. APEX trial: guselkumab achieved 43% ↓ in nail severity score (mNAPSI) vs 16% worsening on placebo at wk 24, plus PASI 100 in ~39% vs 11%. IL-23 inhibition delivering where pts often struggle most. @RheumNow #EULAR2026 POS0471

Jiha Lee JihaRheum ( View Tweet)

Cross-sectional study of 339 IBD pts (64% women, median 42yrs (32–53) found osteopenia by BMD in 34%, OP in 12%. Predictors not identified by multivariable analysis. Rheum eval led to OP Rx in 7% & vitamin D in 45% https://t.co/a9RSo9PxHS https://t.co/nIOR9AUjQs

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective Intl SSc study of MD & PT telangiectasia counts (TC) (0, 1–6, 7–15 or > 15) of face, forearms & hands. High TC correlated w/ PAH (AUC 0.824–0.875) & digital ulcers. Moderate agreement betw MD & Pt for face & forearms TC (kappa 0.648 & 0.605, p< 0.001) https://t.co/k7tVeJFeCi
Dr. John Cush RheumNow ( View Tweet)
Korean claims data on FX in RA (2010-2017; n = 43,677). RA had more FX (aHR 1.68), regardless of b/tsDMARD use. Seropositive had more Fx (aHR 1.19), Vertebral Fx (aHR 1.4) & hip Fx (aHR 1.55) VS seronegative RA https://t.co/5Fm3o841H7 https://t.co/V0L87JYtba

Links:

Dr. John Cush RheumNow ( View Tweet)
Hopkins study of HCQ in discoid lupus (DLE) - 5 yr outcomes of 106 adult DLE; those on HCQ had less hyperlipidemia (HL), PAD, angina, & CAD. Parallel TriNetX study showed HCQ assoc w/ signif less HTN, HL, DM, CAD, & CVA. https://t.co/yX7FkGCnvR https://t.co/oddq68FYeE

Links:

Dr. John Cush RheumNow ( View Tweet)
Trends and Innovations in Lupus Nephritis Clinical Trials Xu et al. from Shanghai University have written an analysis of global lupus nephritis (LN) clinical trials and call for innovation. This systematic review of was informed by 200 interventional pharmacological trials https://t.co/fUTIMhMAis
Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study of 339 IBD pts (64% women, median 42yrs (32–53) found osteopenia by BMD in 34%, OP in 12%. Predictors not identified by multivariable analysis. Rheum eval led to OP Rx in 7% & vitamin D in 45% https://t.co/CNs7hb9KX8 https://t.co/aoesaW1pKw

Links:

Dr. John Cush RheumNow ( View Tweet)
US Biobank (n=480K) study of mobile phone use. W/ 13.6 yrs F/U, 6082 new RA. Cell phone use incr incident RA 14% (HR: 1.14; 1.07–1.23); w/ 8% risk (HR: 1.08) if used >30 min/wk. Speakerphone use was NS. https://t.co/U7TcyoY5SS https://t.co/kqqnFXwaEi

Links:

Dr. John Cush RheumNow ( View Tweet)
VACIMRA RCT in 249 RA pts on MTX were PCV13 vaccinated & continued or held MTX x 4wks. Best humoral responses w/ holding MTX x4wks with no clinical detriment over next 12 mos (remission, LDA, Xray outcomes) https://t.co/b6ByOYY0Fi https://t.co/XeJURKLpL8

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective Intl SSc study of MD & PT telangiectasia counts (TC) (0, 1–6, 7–15 or > 15) of face, forearms & hands. High TC correlated w/ PAH (AUC 0.824–0.875) & digital ulcers. Moderate agreement betw MD & Pt for face & forearms TC (kappa 0.648 & 0.605, p< 0.001) https://t.co/jtHgVABFiA
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×